CAMP4 Therapeutics Corporation Common Stock (CAMP)
Stock · NASDAQ · Health Care
$3.17as of 10/16/2026
Price chart
Active signals
CAMP Signal Track Record
How signals performed across all stocks →What CAMP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 11 | -0.2% | 36% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +3.1% | 57% | September 3, 2026 |
| Bollinger Band Breakout | 6 | -2.2% | 50% | August 14, 2026 |
| Bollinger Band BreakdownActive now | 4 | +6.8% | 50% | July 16, 2026 |
| Any 20-session window (baseline) | +0.9% | 51% |
Computed by MarketWall from daily closing prices since July 31, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CAMP
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Mara…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 48
- Website
- www.camp4tx.com/
Fundamentals
- 1-day range
- $3.27$3.45
- Market cap
- $282.25M
- P/E (trailing)
- —
- P/E (forward)
- -4.04
- EPS (trailing)
- $-2.20
- Dividend yield
- —
- Beta
- -24.51
- Avg. volume
- 271.4K
How CAMP4 Therapeutics Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
CAMP4 Therapeutics Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- CAMPCAMP4 Therapeutics Corporation Common Stock$3.17▼ 8.12%Market cap $282.25MP/E —$2.86$7.75
- ALXOALX Oncology Holdings Inc. Common Stock$1.06▲ 6.00%Market cap $283.93MP/E —$0.8617$2.66
- TTRXTurn Therapeutics Inc. Common Stock$10.57▼ 8.80%Market cap $286.26MP/E —$2.57$26.5
- BCYCBicycle Therapeutics plc American Depositary Shares$3.46▼ 3.89%Market cap $277.87MP/E —$3.33$9.08
- FULCFulcrum Therapeutics Inc. Common Stock$3.65▼ 0.54%Market cap $287.64MP/E —$2.83$15.74
- IMRXImmuneering Corporation Class A Common Stock$3.59▼ 1.37%Market cap $288.55MP/E —$3.6$8.48
- EBSEmergent BioSolutions Inc. Common Stock$6.38▼ 11.14%Market cap $273.98MP/E —$4.36$14.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CAMP CAMP4 Therapeutics Corporation Common Stock | $282.25M | — | $3.17 | ▼ 8.12% | $2.86$7.75 |
| ALXO ALX Oncology Holdings Inc. Common Stock | $283.93M | — | $1.06 | ▲ 6.00% | $0.8617$2.66 |
| TTRX Turn Therapeutics Inc. Common Stock | $286.26M | — | $10.57 | ▼ 8.80% | $2.57$26.5 |
| BCYC Bicycle Therapeutics plc American Depositary Shares | $277.87M | — | $3.46 | ▼ 3.89% | $3.33$9.08 |
| FULC Fulcrum Therapeutics Inc. Common Stock | $287.64M | — | $3.65 | ▼ 0.54% | $2.83$15.74 |
| IMRX Immuneering Corporation Class A Common Stock | $288.55M | — | $3.59 | ▼ 1.37% | $3.6$8.48 |
| EBS Emergent BioSolutions Inc. Common Stock | $273.98M | — | $6.38 | ▼ 11.14% | $4.36$14.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8benzinga · 10/15/2026
- Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6Benzinga · 9/29/2026
- Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day TranscriptSeekingAlpha · 9/28/2026
- CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002Yahoo · 9/28/2026
- Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day - SlideshowSeekingAlpha · 9/28/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 9/11/2026
Insider Activity
Insider Actions →- Kelly Gold · August 31, 2026 · Buy10.0K @ $3.96
- Andrew J. Schwab · August 27, 2026 · Sale400.0K @ $4.04
- Andrew J. Schwab · August 24, 2026 · Sale10 @ $4.5
- Andrew J. Schwab · August 21, 2026 · Sale32.0K @ $4.5
- Andrew J. Schwab · August 20, 2026 · Sale114.7K @ $4.54
- Tardiff Daniel · August 19, 2026 · Sale1.7K @ $4.76
- Andrew J. Schwab · August 19, 2026 · Sale45.1K @ $4.76
- Yuri Maricich · August 3, 2026 · Buy6.6K @ $1.65
- Kelly Gold · August 3, 2026 · Buy6.6K @ $1.65
- Josh Mandel-Brehm · August 3, 2026 · Buy6.6K @ $1.65
- 5AM Partners VI, LLC · August 3, 2026 · Buy3.18M @ $1.53
- Andrew J. Schwab · August 3, 2026 · Grant3.18M @ $1.53
- Richard A. Young · August 3, 2026 · Buy16.4K @ $1.65
- Murray Stewart · June 10, 2026 · Grant28.0K
- Richard A. Young · June 10, 2026 · Grant28.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 39.59M
- Total value held
- $174.53M
- Institutional holders
- 45
- Unknown6.31M
- Unknown5.87M
- Unknown4.93M
- Unknown4.25M
- Unknown2.63M
- Unknown2.19M
- Unknown2.13M
- Unknown1.96M
- Unknown1.94M
- Unknown1.53M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial
CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial. CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.